JAMA Network
About The Study: In this randomized clinical trial of 345 patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound were both common after a standard 5-day course of antiviral treatment with either VV116 or nirmatrelvir-ritonavir. Prolongation of treatment duration might be investigated to reduce COVID-19 rebound.
Authors: Yufang Bi, M.D., and Yiping Xu, M.Sc., of the Shanghai Jiao Tong University School of Medicine in Shanghai, China, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2024.1765)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
